0001415889-22-000714.txt : 20220121 0001415889-22-000714.hdr.sgml : 20220121 20220121204017 ACCESSION NUMBER: 0001415889-22-000714 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220121 FILED AS OF DATE: 20220121 DATE AS OF CHANGE: 20220121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHABER CHRISTOPHER J CENTRAL INDEX KEY: 0001068029 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 22547249 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER NAME: FORMER CONFORMED NAME: SCHABER CHRISTOPHER DATE OF NAME CHANGE: 19980811 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 4 1 form4-01212022_050107.xml X0306 4 2022-01-21 0000812796 SOLIGENIX, INC. SNGX 0001068029 SCHABER CHRISTOPHER J C/O SOLIGENIX, INC. 29 EMMONS DRIVE, SUITE B-10 PRINCETON NJ 08540 true true false false CHAIRMAN, CEO AND PRESIDENT Option (Right to Buy) 0.69 2022-01-21 4 A 0 47315 0 A 2022-01-03 2032-01-02 Common Stock 47315 47315 D The terms of the stock option provide that it is to vest immediately as to 11,829 shares and to vest as to the remainder at a rate of 2,958 of the shares every three months, beginning on April 3, 2022; provided, however, that, consistent with the 2015 Equity Incentive Plan (the "Plan") and the rules of the Nasdaq Stock Market, such stock option shall not be exercisable nor shall it vest prior to the time when an amendment increasing the number of shares authorized for issuance under the Plan is approved by the stockholders, and provided further that, if such approval has not been obtained within 12 months of the grant date, the stock option shall thereupon be canceled and become null and void. The reporting person voluntarily agreed to cancel the stock option granted January 3, 2022 with respect to 47,315 shares. /s/ Christopher J. Schaber 2022-01-21